Theriva Biologics shares are trading lower. The company announced that the FDA granted Rare Pediatric Drug Designation for VCN-01 for the treatment of retinoblastoma.
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics shares are trading lower after the company announced that the FDA granted Rare Pediatric Drug Designation for VCN-01 for the treatment of retinoblastoma.
July 31, 2024 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Theriva Biologics shares are trading lower following the FDA's grant of Rare Pediatric Drug Designation for VCN-01 for retinoblastoma treatment.
Despite the positive news of receiving a Rare Pediatric Drug Designation from the FDA, the market reaction has been negative, leading to a drop in Theriva Biologics' share price. This could be due to investor concerns about the long-term financial implications or the timeline for commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100